

Therasense Revisited: In re Rosuvastatin Calcium Patent Litigation and the Interplay Between Reissue and Inequitable Conduct

APRIL 12, 2013

Reproduced with permission from *Pharmaceutical Law & Industry Report*, 11 PLIR 482 (Apr. 12, 2013). Copyright 2013 by The Bureau of National Affairs, Inc. (800-372-1033) <http://www.bna.com>.

The author states that the Therasense high bar on deceptive intent carried over to the reissue context in Rosuvastatin Calcium Patent Litigation and questions whether a change to the relevant statute in the America Invents Act will have meaningful impact on the inequitable conduct defense.

Less Than 1 Min Read

Author

[Gino Cheng](#)

Related Capabilities

Patent Litigation

Related Professionals



Gino Cheng